First-line nivolumab-ipilimumab in TMB-high NSCLC with was associated with a more than tripled 1-year progression-free survival (PFS) rate compared to platinum-based chemotherapy in the Phase III CheckMate 227 trial (NCT02477826).
What is new in oncology translational research? Read our oncology translational research blog and learn more about the advancements in oncology translational research.
Frontline pembrolizumab (KeytrudaⓇ) plus standard platinum-based chemotherapy reduces the risk of death by more than 50% in patients with nonsquamous non–small cell lung cancer (NSCLC) not harbouring EGFR or ALK genetic aberrations, as shown by the Phase III KEYNOTE-189 (NCT02578680).
Pembrolizumab (Keytruda®) as single-agent immunotherapy in the frontline setting of any histology NSCLC with a PD-L1 expression ≥1% was associated with improved overall survival (OS) when compared to platinum-doublet chemotherapy in the KEYNOTE-042.
The CICS Annual Conference on Immuno Oncology is offering the most significant advances in the world of oncology. The goal of the meeting is to convey the clinical and translational advances in various areas of cancer immunology to medical oncologists, medical students, and other health professionals.
The United States Food and Drug Agency (US FDA) require the development of companion diagnostics (CDx). CDx can help to identify patients at risk and guide patient selection. Moreover, it serves as a marker for treatment outcome. Thus enabling physicians to better balance safety with efficacy. The US FDA motivates the development of a CDx in early stages of clinical studies.
The number of different types of T-helper cells (Th) and cytotoxic T cells (CD8) may predict response to ipilimumab in several malignancies. This was concluded by Dr Juan Pablo Márquez Manríquez who presented the study at the ESMO conference on behalf of the investigators of the Sonora Cancer Research Center (CICS) in Mexico and the United States (U.S.).
Recent studies have shown new possible applications for Ki67. Huh et al. showed that low Ki67 levels in healthy breast tissue correlated with a lesser lifetime chance of breast cancer. Another study by Arnedos and colleagues concluded that palbociclib was able to invoke a significant Ki67-level drop. After a decade of Ki67-controversies, these results put the marker back in the spotlight.